NanoBio Corporation, which is developing a several intranasal vaccines, has announced that David Peralta will succeed James R. Baker as the company’s Chief Executive Officer after Baker was hired by Merck as Senior VP, Head Global Vaccine Franchise. In 2011, NanoBio announced a collaboration with Merck on an intranasal RSV vaccine. Peralta has worked for NanoBio since 2006 in business development and finance and had been the company’s COO and CFO.
Peralta commented, “I am honored and excited to lead NanoBio. I believe that NanoBio can play a very important role in the future of medicine. We are on the forefront of harnessing nanotechnology to safely treat some of the most troublesome skin and lung infections. In addition, we are making great strides in terms of utilizing our NanoStat technology to enable intranasal and intramuscular vaccines for diseases that today have no vaccine available. I wish Jim all the best in his new role at Merck, and I look forward to continuing to work closely with him as a member of our board of directors.”
Read the NanoBio press release.
